One of our patients with CML-BC/Ph+ ALL (no. 69) acquired an additional TP53 (V216M)variant during ponatinib treatment (in 12% reads), a mutation known to be associated with breast cancer [41,42]. This evidence concerns the gene TP53 and breast cancer.